Compare Hut 8 Corp (HUT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Novartis AG — how do they compare? Hut 8 Corp trades at $81 (market cap $9.82B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 27.3× Hut 8 Corp's market cap, and Novartis AG pays a 3.31% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Novartis AG for 82 Days on average.
| HUT | NVS | |
|---|---|---|
Market Cap | $9.82B | $268.57B |
Volume | 10,272,678 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $133.02 | $168.62 |
52-Week Low | $33.76 | $121.80 |
Typical Hold Time | 11 Days | 82 Days |
Enterprise Value | $17.25B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $89.3, down 3.17% today, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net margin, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and AI infrastructure deals, fueling optimism. Analyst consensus is strongly bullish with a $156.79 price target.
The outlook balances strong analyst support and AI infrastructure growth potential against persistent losses and high valuation multiples. Key risks include execution on profitability and competitive pressures in the digital infrastructure space.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
